Myeloma Patients Europe

29/07/2025

Alongside last week’s news on belantamab mafodotin and daratumumab, there was more good news: isatuximab has been approved by the European Commission for use in transplant-eligible, newly diagnosed myeloma patients in combination with bortezomib, lenalidomide and dexamethasone.

📰 Read our full news update here:
👉 https://www.mpeurope.org/approval-for-isatuximab-for-transplant-eligible-newly-diagnosed-myeloma-patients/

| Learn more about myeloma and AL amyloidosis at the website.

25/07/2025

𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆!

The European Commission has today granted final authorisation for two belantamab mafodotin (Blenrep®) combinations to be used across the EU for relapsed/refractory myeloma patients who have received at least one prior line of therapy.

The two new treatment combinations now approved are:
- Blenrep plus bortezomib and dexamethasone (BVd)
- Blenrep plus pomalidomide and dexamethasone (BPd)

The approval is based on positive results from the DREAMM-7 and DREAMM-8 phase III trials, which showed extended progression-free survival compared to standard of care.

As our co-CEO Kate Morgan notes: "The more treatments we have, including new mechanisms of action such as belantamab mafodotin, the more effectively we are able to treat myeloma."

While this EU-wide marketing authorisation confirms safety and efficacy, patient access will vary greatly and depend on national healthcare system decisions. We'll continue our work with stakeholders across Europe to improve access for patients who need it.

Read more at https://www.mpeurope.org/the-european-commission-grants-final-authorisation-for-belantamab-mafodotin-blenrep-combinations-for-relapsed-refractory-myeloma-patients/

hashtag hashtag hashtag hashtag hashtag

| Learn more about myeloma and AL amyloidosis at the website.

24/07/2025

The European Commission (EC) has approved a new indication for daratumumab (Darzalex®) for the treatment of adult patients with smouldering myeloma (SMM) at high-risk of developing myeloma. This follows a positive recommendation from the Committee for Medicinal Product for Human Use (CHMP) in June 2025. The CHMP is the European Medicines Agency’s (EMA) committee playing a significant role in the assessment and authorisation of human medicines.

Learn more about it here:

| Learn more about myeloma and AL amyloidosis at the website.

23/07/2025

A huge thank you to all our MPE members who joined us in person at our Central and Eastern Europe workgroup meeting yesterday in Zurich and contributed to an inspiring day of discussion, exchange and forward planning.

A report and actions from the meeting will be available soon!

We are proud to support your work and look forward to strengthening collaboration across CEE in the years to come.

14/07/2025

𝗡𝗲𝘄 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗮𝗻𝗱 𝘀𝗺𝗼𝘂𝗹𝗱𝗲𝗿𝗶𝗻𝗴 𝗺𝘆𝗲𝗹𝗼𝗺𝗮


New guidelines published for doctors and healthcare professionals: The European Hematology Association (EHA) and European Myeloma Network (EMN) have published comprehensive new guidelines for myeloma and smouldering myeloma treatment in Nature Reviews Clinical Oncology.

𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

- 14 new treatment regimens approved by EMA/FDA

- Enhanced recommendations for newly diagnosed patients, including anti-CD38 monoclonal antibodies as first-line treatment

- Expanded options for relapsed patients, including CAR T-cell therapies and bispecific antibodies

- Updated guidance on managing complications and adverse events

As 𝗗𝗿. 𝗠𝗲𝗹𝗲𝘁𝗶𝗼𝘀 𝗗𝗶𝗺𝗼𝗽𝗼𝘂𝗹𝗼𝘀, Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, in Greece, notes: "𝘛𝘩𝘦𝘴𝘦 𝘶𝘱𝘥𝘢𝘵𝘦𝘥 𝘳𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥𝘢𝘵𝘪𝘰𝘯𝘴 𝘸𝘪𝘭𝘭 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘢𝘯 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺 𝘧𝘰𝘳 𝘮𝘺𝘦𝘭𝘰𝘮𝘢 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘵𝘰 𝘳𝘦𝘤𝘦𝘪𝘷𝘦 𝘵𝘩𝘦 𝘣𝘦𝘴𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘢𝘯𝘥 𝘸𝘪𝘭𝘭 𝘩𝘢𝘳𝘮𝘰𝘯𝘪𝘴𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘱𝘳𝘢𝘤𝘵𝘪𝘤𝘦𝘴 𝘢𝘭𝘰𝘯𝘨 𝘢𝘭𝘭 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴."

These evidence-based guidelines are a significant step forward in delivering optimal care for myeloma patients across Europe.

Read more
https://www.mpeurope.org/new-guidelines-for-doctors-and-healthcare-professionals/

| Learn more about myeloma and AL amyloidosis at the website.

11/07/2025

𝗠𝗣𝗘 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿𝗪𝗼𝗿𝗹𝗱 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗘𝗨 𝗛𝗧𝗔𝗥 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻!

The EU's new Health Technology Assessment Regulation (HTAR), launched in January 2025, aims to streamline approvals for new medicines across Europe. Currently, patients face long waits and unequal access to innovative therapies depending on which EU country they live in. In the latest edition of CancerWorld, Sophie Fessl interviewed MPE’s own Access and Policy Manager, Monica Racovita, to explore the new regulation and its impact on patients and patient organisations.

𝗛𝗧𝗔𝗥 𝘂𝗹𝘁𝗶𝗺𝗮𝘁𝗲𝗹𝘆 𝗮𝗶𝗺𝘀 𝘁𝗼:

- Streamline approval processes and thus, hopefully reduce delays
- Ensure patient and clinician input are at the heart of the process

While HTAR aims to bring these great benefits and opportunities, it also brings uncertainties that need to be worked through:

- The role of patient organisations in the process
- Conflict of interest requirements for patient and clinician experts
- Role of the JCA (joint clinical assessments) report in national decisions

This regulation could be a major step forward for patient access to life-changing treatments. Read the article here (Starting on page 31)https://cancerworld.net/wp.../uploads/2025/07/CW5-Web.pdf

09/07/2025

Multiple Myeloma Ireland, MPE’s Irish member, recently hosted a Patient and Family Information Day. Over 100 patients, carers, and healthcare professionals came together for a successful event.

This event was featured in our latest member newsletter and is the kind of member-led initiative that we love to see!

Click to read more about the speakers, the day itself, and the work of Multiple Myeloma Ireland

Find out more about Multiple Myeloma Ireland and their Patient and Families information day.

02/07/2025

During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews highlighting the most important updates in myeloma. These interviews focused on key research findings and their potential to improve patient survival and quality of life.
🎥 Watch the full series: https://www.mpeurope.org/eha-2025-expert-interviews/


📺 Don’t miss the recording of our webinar “EHA 2025 Highlights”!
Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at Södra Älvsborgs sjukhus and Sahlgrenska University Hospital, Sweden, shares his top takeaways in myeloma from the Congress.
▶️ Watch now: https://www.youtube.com/watch?v=OB1rdrTBu60&feature=youtu.be

| Learn more about myeloma and AL amyloidosis at the website.

28/06/2025

🧬 What role does cytogenetics play in myeloma?

Genetic testing can identify mutations present in high-risk myeloma, a subtype of the disease that tends to progress more aggressively and respond less favourably to standard treatments. Recognising high-risk features early enables haematologists to tailor treatment strategies accordingly.

MPE has published a new educational Q&A explaining how tests like FISH are used to identify high-risk genetic changes and guide treatment decisions.

📘 Read the full article here: https://www.mpeurope.org/what-we-do/educational-resources/qas/cytogenetics-and-risk-testing-in-myeloma/

Discover the similarities and differences between myeloma and AL amyloidosis, common symptoms and the treatment for both diseases.

26/06/2025

🎥 Watch the recording of our webinar: "EHA 2025 Highlights"!
Presented by Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at Södra Älvsborgs sjukhus and Sahlgrenska University Hospital, Sweden.

In this session, Dr. Mellqvist shares his key myeloma takeaways from the European Hematology Association (EHA) Annual Congress, held this month in Milan, Italy.

📺 Watch here: https://www.youtube.com/watch?v=OB1rdrTBu60&feature=youtu.be

🧠 Don’t miss our expert interview summarising the most important myeloma clinical trials presented at EHA 2025:
👉 https://www.mpeurope.org/eha-2025-expert-interviews/

Recording of the webinar organised to summarise the most important myeloma updates presented at the European Hematology Association (EHA) Annual Congress 202...

20/06/2025

🎯Want to catch up on the most important updates from the congress?

📆Join our upcoming EHA 2025 Highlights Webinar on Tuesday, 24 June at 17:00 CET, designed to help patients and advocates digest the key news from the event.

The session will be led by Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at Södra Älvsborgs sjukhus and Sahlgrenska University Hospital, Sweden.
He will provide a patient-friendly summary of key takeaways and answer your questions live.

Register now 👇

| To digest the most important myeloma news from the European Hematology Association (EHA) 2025 Congress, MPE will host a webinar on 24 June at 17:00 CET.

17/06/2025

MPE interviewed Francesco Sparano from Fondazione GIMEMA Franco Mandelli onlus on results from the GIMEMA-CLARITY study on the link between quality of life and socio-economic status of myeloma patients in Italy and the UK. The study was presented at the Euroepan Hematology (EHA) Annual Congress 2025. held in Milan, Italy.

Watch here 👇🏼

https://youtu.be/Ig3FQifCbm0?si=QMWjnZ1dFlmTbhAi

Myeloma Patients Europe (MPE) interviewed Francesco Sparano from Fondazione GIMEMA Franco Mandelli onlus on results from the GIMEMA-CLARITY study on the link...